AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...

Healthcare giants AbbVie and Abbott Laboratories are both Dividend Kings. In 2013, AbbVie (NYSE: ABBV) became a publicly ...

AbbVie Q4 adjusted EPS of $2.16 beat estimates, with strong sales of Skyrizi (+57.9%) and Rinvoq (+47.1%) boosting revenue growth. AbbVie raises 2027 revenue forecast for Skyrizi and Rinvoq to $31 ...

This outperformance is indicative of investor confidence in the pharmaceutical giant's ambitious transformation strategy as it navigates the post-Humira period.

Tremfya snagged Dupixent’s place as the pharma brand with the most TV impressions in June, according to data released by iSpot.tv on Friday morning. The Johnson & Johnson brand garnered a 4.3% share ...

AbbVie’s $2.1 billion acquisition of Capstan Therapeutics aims to advance in vivo CAR-T therapies, transforming autoimmune disease treatment by resetting the immune system.